2010
DOI: 10.1111/j.1939-1676.2010.0623.x
|View full text |Cite
|
Sign up to set email alerts
|

Letter to the Editor

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2017
2017
2017
2017

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 4 publications
(7 reference statements)
0
1
0
Order By: Relevance
“…Urinary aldosterone to creatinine ratio (UAC) is associated with the rate of change of left ventricular size in dogs with MMVD, suggesting that aldosterone production increases during periods of active remodelling [13]. Spironolactone is a mineralocorticoid receptor antagonist that has been shown to prolong survival times in dogs with advanced MMVD and CHF secondary to MMVD, when given in combination with standard therapy [14]. The use of spironolactone in dogs with compensated MMVD has not been reported, although a study investigating its effects in combination with benazepril is currently ongoing.…”
Section: Introductionmentioning
confidence: 99%
“…Urinary aldosterone to creatinine ratio (UAC) is associated with the rate of change of left ventricular size in dogs with MMVD, suggesting that aldosterone production increases during periods of active remodelling [13]. Spironolactone is a mineralocorticoid receptor antagonist that has been shown to prolong survival times in dogs with advanced MMVD and CHF secondary to MMVD, when given in combination with standard therapy [14]. The use of spironolactone in dogs with compensated MMVD has not been reported, although a study investigating its effects in combination with benazepril is currently ongoing.…”
Section: Introductionmentioning
confidence: 99%